Contrasting INVO Bioscience (NASDAQ:INVO) and Glaukos (NYSE:GKOS)
Contrasting INVO Bioscience (NASDAQ:INVO) and Glaukos (NYSE:GKOS)
INVO Bioscience (NASDAQ:INVO – Get Rating) and Glaukos (NYSE:GKOS – Get Rating) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.
纳斯达克(股票代码：INVO-GET)和Glaukos(纽约证券交易所代码：GKOS-GET)都是医药公司，但哪只股票更好？我们将根据这两家公司的盈利能力、估值、风险、股息、机构所有权、分析师推荐和收益等方面的实力进行比较。
Earnings & Valuation
收益与估值
This table compares INVO Bioscience and Glaukos' revenue, earnings per share and valuation.
此表比较了INVO Bioscience和Glaukos的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| INVO Bioscience | $4.16 million | 4.51 | -$6.66 million | N/A | N/A |
| Glaukos | $294.01 million | 9.18 | -$49.59 million | ($1.19) | -47.93 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| INVO生物科学 | 416万美元 | 4.51 | -666万美元 | 不适用 | 不适用 |
| 格劳科斯 | 2.9401亿美元 | 9.18 | -4,959万元 | ($1.19) | -47.93 |
INVO Bioscience has higher earnings, but lower revenue than Glaukos.
与Glaukos相比，INVO Bioscience的收益更高，但收入更低。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| INVO Bioscience | -222.62% | -165.97% | -92.06% |
| Glaukos | -19.35% | -13.82% | -7.73% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| INVO生物科学 | -222.62% | -165.97% | -92.06% |
| 格劳科斯 | -19.35% | -13.82% | -7.73% |
Insider & Institutional Ownership
内部人与机构所有权
11.8% of INVO Bioscience shares are owned by institutional investors. Comparatively, 93.1% of Glaukos shares are owned by institutional investors. 10.4% of INVO Bioscience shares are owned by company insiders. Comparatively, 8.1% of Glaukos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
INVO Bioscience 11.8%的股份由机构投资者持有。相比之下，Glaukos 93.1%的股份由机构投资者持有。INVO Bioscience 10.4%的股份由公司内部人士持有。相比之下，Glaukos 8.1%的股份由公司内部人士持有。强大的机构持股表明，大型基金管理公司、捐赠基金和对冲基金相信，一家公司的长期表现将好于大盘。
Volatility and Risk
波动性和风险
INVO Bioscience has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.42, indicating that its stock price is 42% more volatile than the S&P 500.
INVO Bioscience的贝塔系数为0.19，表明其股价的波动性比标准普尔500指数低81%。相比之下，Glaukos的贝塔系数为1.42，这表明其股价的波动性比标准普尔500指数高出42%。
Analyst Ratings
分析师评级
This is a summary of recent ratings and price targets for INVO Bioscience and Glaukos, as provided by MarketBeat.
这是由MarketBeat提供的INVO Bioscience和Glaukos最近的评级和目标价摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| INVO Bioscience | 0 | 1 | 2 | 0 | 2.67 |
| Glaukos | 1 | 4 | 4 | 0 | 2.33 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| INVO生物科学 | 0 | 1 | 2 | 0 | 2.67 |
| 格劳科斯 | 1 | 4 | 4 | 0 | 2.33 |
INVO Bioscience presently has a consensus target price of $2.50, suggesting a potential upside of 62.34%. Glaukos has a consensus target price of $57.38, suggesting a potential upside of 0.59%. Given INVO Bioscience's stronger consensus rating and higher possible upside, equities analysts clearly believe INVO Bioscience is more favorable than Glaukos.
INVO Bioscience目前的共识目标价为2.50美元，暗示潜在上涨62.34%。Glaukos的共识目标价为57.38美元，暗示潜在上行0.59%。鉴于INVO Bioscience更强劲的共识评级和更高的可能上行空间，股票分析师显然认为INVO Bioscience比Glaukos更有利。
Summary
摘要
Glaukos beats INVO Bioscience on 8 of the 12 factors compared between the two stocks.
Glaukos在两只股票比较的12个因素中有8个超过了INVO Bioscience。
About INVO Bioscience
关于INVO生物科学
(Get Rating)
(获取评级)
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.
INVO Bioscience，Inc.是一家商业阶段的生育公司，在全球提供辅助生殖技术解决方案。它的旗舰产品是INVOcell，这是一种医疗设备，可以在女性体内进行受精和早期胚胎发育。该公司成立于2007年，总部设在佛罗里达州萨拉索塔。
About Glaukos
关于格劳科斯
(Get Rating)
(获取评级)
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Glaukos公司是一家眼科医疗技术和制药公司，专注于开发治疗青光眼、角膜疾病和视网膜疾病的新疗法。该公司提供iStent、iStent注射、iStent注射W型微旁路支架，这些支架可增强白内障手术中植入的房水流出，以治疗轻至中度开角型青光眼。该公司的产品线包括iStent InLimited，一种三支架产品，设计用于难治性青光眼患者的独立手术；以及iDose tr，一种基于其微型设备平台的定向可注射植入物，旨在提供治疗水平的药物。该公司通过直销机构以及美国和国际分销商销售其产品。Glaukos公司成立于1998年，总部设在加利福尼亚州圣克莱门特。
Receive News & Ratings for INVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
获得INVO生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对INVO Bioscience和相关公司的最新新闻和分析师评级的每日简要摘要。